Diversified Client Base
No Client Over 5% of Revenues – High Repeat Business
- Relationships with all large-cap pharma and biotech
- Links with leading academic and research institutions
- Full-service partner to emerging biotech
Source: Based on Charles River and Inveresk 2003 management estimates.